

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**




PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61L 25/00, 27/00	AI	(11) International Publication Number: WO 99/19003 (43) International Publication Date: 22 April 1999 (22.04.99)
(21) International Application Number: PCT/US98/20803 (22) International Filing Date: 2 October 1998 (02.10.98) (30) Priority Data: 60/062,108 14 October 1997 (14.10.97) US 09/079,884 15 May 1998 (15.05.98) US (71) Applicant: BATTELLE MEMORIAL INSTITUTE [US/US]; Pacific Northwest Division, Intellectual Property Services, P.O. Box 999, Richland, WA 99352 (US). (72) Inventors: ARMSTRONG, Beth, L.; 6817 West Wernett Road, Pasco, WA 99301 (US). CAMPBELL, Allison, A.; 1515 West 16th, Kennewick, WA 99337 (US). GUTOWSKA, Anna; 450 Mateo Court, Richland, WA 99352 (US). SONG, Lin; 464 Mainmast Court, Richland, WA 99352 (US). (74) Agent: ZIMMERMAN, Paul, W.; Battelle Memorial Institute, Pacific Northwest Division, Intellectual Property Services, P.O. Box 999, Richland, WA 99352 (US).	(81) Designated States: CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	

(54) Title: IMPLANTABLE POLYMER/CERAMIC COMPOSITES



(57) Abstract

The present invention provides a composition which comprises a polymer or polymer solution that forms a gel under controlled parameters and a ceramic matrix, the composition being fluid under non-physiological conditions and non fluid under physiological conditions. Polymers may be resorbable or non-resorbable, natural or synthetic and the solution aqueous or non-aqueous. Preferred polymers are polysaccharides, polyamides or polyamino acids; however, any polymer or polymer solution that is biologically compatible and that is fluid under nonphysiological conditions and increases in viscosity under physiological conditions is suitable. Stimuli sensitive gel means a natural or synthetic polymer that increases in viscosity, gels or crosslinks in response to a stimulus such as a change in temperature, pH, ionic strength, light or the like. In contrast to the rigid composites synthetic grafts of the prior art, the compositions of the present invention may be injected at a trauma site, such as a fracture and shaped to fill any voids present, forming an in situ splint and scaffold for the growth of new bone.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

POLYMER/CERAMIC COMPOSITES

TECHNICAL FIELD

5

The present invention relates to a method for constructing an implant by placement of a paste comprising a stimuli sensitive polymer solution carrying a biocompatible ceramic component, which hardens under physiological conditions to form a solid implant. The implant may also include a therapeutic agent or a
10 radioisotope.

BACKGROUND OF THE INVENTION

Many researchers have experimented with drug delivery vehicles based on
15 the use of controlled release implant materials. Others have sought to provide improved implants for filling in tissue losses from age or trauma, to hard or soft tissues. Calcium phosphate pastes have been suggested as bone and dental fillers. Gels have been used as control release devices and as fillers. Representative studies are discussed below.

20

In U.S. Patent No. 4,188,373, certain polyols are used in aqueous compositions to provide thermally gelling aqueous systems. In these systems, the sol-gel transition temperature can be changed by manipulating the concentration of polymer. In U.S. Patent Nos. 4,474,751; '752; '753; and 4,478,822 drug delivery systems are described which utilize thermosetting gels. In these systems,
25 both the gel transition temperature and/or the rigidity of the gel can be modified by adjustment of the pH and/or the ionic strength, as well as by the concentration of the polymer. U.S. Patent Nos. 4,883,660; 4,767,619; 4,511,563; 4,861,760, and 4,911,926 also disclose gels that deliver pharmaceutical compositions.

In U.S. Patent No. 4,895,724, compositions are disclosed for the controlled
30 release of pharmacological macromolecular compounds contained in a matrix of chitosan. Chitosan can be cross-linked utilizing aldehydes, epichlorohydrin,

benzoquinone, etc. In U.S. Patent No. 4,795,642, discloses gelatin-encapsulated, controlled-release pharmaceutical compositions, wherein the gelatin encloses a solid matrix formed by the cation-assisted gelation of a liquid filling composition incorporating a vegetable gum together with a pharmaceutically-active compound.

5 The vegetable gums are disclosed as polysaccharide gums such as alginates, which can be gelled utilizing a cationic gelling agent such as an alkaline earth metal cation.

Osmotic drug delivery systems are disclosed in U.S. Patent No. 4,439,196 which utilize a multi-chamber compartment for holding osmotic agents, adjuvants, enzymes, drugs, pro-drugs, pesticides, and the like. These materials are enclosed
10 by semipermeable membranes so as to allow the fluids within the chambers to diffuse into the environment into which the osmotic drug delivery system is in contact. U. S. Patent No. 5,587,175 teaches a process for forming a protective corneal shield or an ablatable corneal shield or mask in situ comprising
15 administering to the eye of a mammal an aqueous composition capable of being gelled in situ to produce an hyper osmotic, hypo osmotic, or iso osmotic aqueous gel having a controlled pH, said aqueous composition, including at least one film forming polymer; and gelling said film forming polymer in situ to form said protective corneal shield or ablatable corneal shield or mask.

20 U.S. Patent No. 3,949,073 discloses injectable atelocollagen solutions which precipitate at body temperature, thus leading to the formation of fibers which remain at the injection site whereas the excipient is progressively resorbed. U. S. Pat. No. 5,658,593 in one embodiment provides micro capsules based on atelocollagen optionally mixed with a glycosaminoglycan such as
25 chondroitin-4-sulfate, the micro capsules containing granules of hydroxyapatite in suspension in a viscous bio compatible carrier solution of a gel of atelocollagen optionally mixed with a glycosaminoglycan, in particular chondroitin-4-sulfate, for use as a filler material in forming injectable implants.

U. S. Patent No. 5,626,861 teaches a method for the fabrication of
30 three-dimensional macro porous polymer matrices for use as bone graft or implant

material was developed. The composites are formed from a mixture of biodegradable, bio compatible polymer and hydroxyapatite (HA), a particulate calcium phosphate ceramic. The method leaves irregular pores in the composite between 100 and 250 microns in size by formation of a solid gel comprising a soluble material and dissolving the material to form voids in the gel. In a preferred embodiment, implants are composed of a 50:50 poly(lactide-co-glycolide) (PLGA) polymer and reinforced by hydroxyapatite. Mechanical and histological analysis showed the matrix fabricated by this method to be structurally and mechanically similar to cancellous bone. Prior to degradation, pure polymer specimens exhibited an elastic modulus of 293 Mpa, and specimens, which were 50% HA by weight, exhibited a modulus of 1459 MPa. After six weeks of degradation under physiological conditions, the reinforcing effect of ceramic loading had diminished. Modulus of polymer matrices at all HA load levels had decreased sharply to approximately 10 MPa. Mean macro- and micro pore diameters of the polymer specimens were 100 μ m and 20 μ m, respectively, and remained constant throughout degradation. The implants are hardened, leached and then implanted into the subject where they are slowly degraded by natural bodily action over a period of time. The implant size and shape must be predetermined and thus may not perfectly fit the site to be repaired.

B. R. Constantz, *et als*, 1995, Skeletal Repair by in Situ Formation of the Mineral Phase of Bone, *Science*, 267:1796-1799; discloses a process for the surgical implantation of a paste that hardens in minutes under physiological conditions. The mixture comprises a mixture of calcium phosphates and sodium phosphate, and hardens due to the crystallization of dahlite, not mediated by a stimulus setting gel. The mixture hardens regardless of whether it is placed in the body. The paste is a hydroxyapatite precursor and does not include gel components.

B. Flautre, *et als*, 1996, Evaluation of Hydroxyapatite Powder Coated with Collagen as an Injectable Bone Substitute: Microscopic Study in Rabbit, *J.*

Materials Science: Materials in Medicine, 7:63-67, discloses an injectable mix of hydroxyapatite and collagen, but there is no disclosure of providing a stimulus response setting material. The group uses HA and atecollegen and chondrotin-4-sulfate formulated as micro spheres, similar to the patents discussed above. There is no provision for a gel, which forms in response to a stimulus provided by exposure to the environment of the body, and there is no provision for differential loss of materials to provide a porous matrix. A further study by the same group, G. Pasquier, *et als*, 1996, Injectable Percutaneous Bone Biomaterials: an Experimental Study in a Rabbit Model, *J. Materials Science: Materials in Medicine*, 7:683-690, discloses mixtures comprising an orthopaedic acrylic cement (polymethylmethacrylate ("PMMA")) and HA as well as HA and collagen. The PMMA was used as a reference bio-inert material. There is no disclosure of a stimulus setting gel for producing a composite, which only hardens in response to a stimulus supplied by the body.

M. Ito, *et als*, 1994, Experimental Development of a Chitosan-bonded Tricalcium Phosphate Bone Filling Paste, *Bio-Medical Materials and Eng.*, 4:439-499, discloses a composite of chitosan and tricalcium phosphate containing alkaline oxides of calcium, magnesium or zinc, which provided the conditions to produce setting. Again the material hardens without regard to stimulus supplied from the body. A similar study is reported by M. Takechi, *et als*, 1996, Non-decay Type Fast-setting Calcium Phosphate Cement Using Chitosan, *J. Materials Science: Materials in Medicine*, 7:317-322. Takechi uses sodium alginate or chitosan as a water insoluble gel to protect calcium phosphate cements from decay during setting under physiological conditions. In these materials the cements set as they normally do, and the gel forms in response to the calcium provided by the cement. Again there is no gel formation in response to a physiological stimulus for the composite material.

There is a continuing and long felt need for alternative implant materials for the treatment of damage to bony tissues by injury or disease. The art has not heretofore provided a fluid or shapeable implant material which comprises both a

bone growth supporting matrix such as a ceramic matrix, and a stimulus sensitive gel which can be shaped to fill an injury site and then hardens to support the injured tissue during healing. The art has not heretofore provided a polymer/ceramic composite suitable for use in bone repair wherein a stimuli sensitive gel is used as a fluid carrier to place a ceramic matrix into a damaged bony tissue wherein the gel hardens in response to a physiological condition such as temperature, pH, ionic strength and the like in the presence of the ceramic.

SUMMARY OF THE INVENTION

10

The present invention provides a composition which comprises a polymer or polymer solution that forms a gel under controlled parameters and a ceramic matrix, the composition being fluid under non-physiological conditions and non fluid under physiological conditions. Polymers may be resorbable or nonresorbable, natural or synthetic and the solution aqueous or non-aqueous. Preferred polymers are poly- saccharides, polyamides or polyamino acids; however, any polymer or polymer solution that is biologically compatible and that is fluid under nonphysiological conditions and increases in viscosity under physiological conditions is suitable. As used in this application, physiological conditions means conditions normally found in a mammalian body such as pH in the range of 4 to 9, ionic strength of around 0.15 or temperature in the range of 35-40°C. Stimuli sensitive gel means a natural or synthetic polymer that increases in viscosity, gels or crosslinks in response to a stimulus such as a change in temperature, pH, ionic strength, light or the like. In contrast to the rigid composites synthetic grafts of the prior art, the compositions of the present invention may be injected at a trauma site, such as a fracture and shaped to fill any voids present, forming and in situ splint and scaffold for the growth of new bone. The composite may also serve as a controlled release device for a therapeutic agent such as a bone growth factor, an antibiotic, a chemotherapy drug, or a cytokine. The composites may include bone morphogenic proteins or other

30

osteoconductive agents. Preferably the composites are formed in such a manner that the final solid implant is porous with macroscopic pores, preferably on the order of 100 to 200 microns in cross section. In an alternative embodiment, a near net shape forming composition is employed wherein the polymer is a bio compatible, shear thinning polymer that forms a gel under ambient pressure and a ceramic component carried therein. The shear-thinning polymer is one in which the polymer viscosity decreases in response to a stimulus such as ultrasonic vibration or injection.

Alternatively, the invention may be viewed as a method of forming a solid implant in a mammalian body which comprises mixing a gel forming component with a ceramic forming component to provide a fluid mixture, placing the fluid mixture into a mammalian body wherein the fluid mixture gels after placement in the mammalian body in response to a stimulus provided by conditions present or induced in the mammalian body. Conditions present in the mammalian body includes normal body temperature, ionic strength, pH and the like. Conditions that can be induced in the body include ultrasonic vibration, externally applied magnetic fields, irradiation from a radiation source or light or other electromagnetic radiation. Preferably, the fluid mixture comprises a gel forming polymer, a calcium phosphate ceramic, and a soluble material which will produce voids in the final implant, the voids having an average cross section in the range of 100 to 200 microns. The soluble material is preferably a second polymer, which degrades or dissolves relatively rapidly under physiological conditions. Especially preferred polymers dissolve by enzymatic action, leaving non-toxic, non-irritating residues.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a plot of the viscosity of 30 wt% hydroxyapatite (HAP) slurries with different polymers.

Figure 2 is a plot of solids loading effect on the viscosity of HAP in 0.4 wt% carrageenan.

Figure 3 is a plot of solids loading for three polysaccharide polymers.

Figure 4 is a plot of temperature against viscosity carrageenan and HAP carrageenan suspensions.

Figures 5a and 5b are Scanning Electron Micrographs showing the structures of 30 wt% HAP in 2 wt% carrageenan (a) and 40 wt% HAP in 2 wt% carrageenan (b).

Figure 6 is a plot of the dissolution of HAP/carrageenan composite and HAP powder at pH 6.5 in a solution containing 0.125 mM CaCl_2 , 0.075 mM KH_2PO_4 and 0.15 M NaCl.

Figure 7 is a plot of the fraction of carrageenan leached from the composition in a simulated blood plasma solution at 37°C against time.

Figure 8 is a plot of the viscosity of chitosan/HAP suspensions as a function of HAP wt% in 0.1N acetic acid.

Figure 9 is a plot of the compression modulus of chitosan/HAP composites showing the effect of solids loading.

Figure 10 is a plot of the compression modulus of HMW chitosan/HAP and chitosan/TCP showing the effect of the ceramic calcium phosphate phase.

Figure 11 is a plot of the release of 5-fluorouracil from chitosan/HAP and chitosan/TCP compositions.

Figure 12 is a plot comparing release of 5 fluorouracil and bovine serum albumin from a chitosan/HAP composition.

DETAILED DESCRIPTION OF THE INVENTION

Mechanisms by which bone may fail include brittle fracture from impact loading and fatigue from constant or cyclic stress. Stresses may act in tension, compression, or shear along one or more of the axes of the bone. A synthetic bone substitute must resist failure by any of these stresses at

their physiological levels. A factor of safety on the strength of the implant may ensure that the implant will be structurally sound when subject to hyper physiological stresses. The solid implants of the prior art all require the injured bone to conform to the shape of the implant, requiring invasive surgery, long recovery times, fixation devices inserted into the bone, rigid external or internal splints and ingrowth of bone into the implant ("knitting"). Especially in the elderly, implants may fail due to failure of the bone regrowth and therefore failure of the implant to become joined to the bone. The rigid implant of U. S. Patent No. 5,626,861 exemplifies the traditional approach of forming the implant ex vivo followed by surgical insertion into the injured bone.

In contrast to the prior art approach, it has now been found that stimuli sensitive gels can be combined with bone precursors such as hydroxyapatite ceramic particles to permit placement of fluid materials into damaged bone. The fluid mixtures form rigid structures on exposure to physiological conditions, forming the implant as an integral part of the bony structure. The hardening of the implant may be triggered by any stimuli that can be provided directly or indirectly under physiological conditions. Examples of direct stimuli include temperature, pH, ionic strength, and the like, as they occur in a mammalian body. Examples of indirect stimuli that may be applied under physiological conditions include external heating or cooling, light and other electromagnetic radiation across the broad range of the spectrum, magnetic fields, induced or applied electrical charge or current, and the like.

A variety of bio compatible polymers can be used. The stimulus sensitive polymer may be any bio compatible polymer or copolymer which forms a gel or crosslinked structure in response to a stimulus which may include temperature, pH, ionic strength, solvent composition, shear stress, light, and the like or a combination of these factors. Preferred polymers are described in co-pending application Serial No 08/870,368, filed June 6, 1997, incorporated herein by reference. Preferred stimulus sensitive polymers are random copolymers of a [meth-]acrylamide derivative and a hydrophilic comonomer, wherein the random

copolymer is in the form of a plurality of linear chains having a plurality of molecular weights greater than or equal to a minimum gelling molecular weight cutoff.

The [meth-]acrylamide derivative is an N, N'-alkyl substituted
5 [meth-]acrylamide including but not limited to N-isopropyl[meth-]acrylamide, N,N'-diethyl[meth-]acrylamide, N-[meth-]acryloylpyrrolidine, N-ethyl[meth-]acrylamide, and combinations thereof.

The hydrophilic co monomer is any hydrophilic co monomer that polymerizes with the [meth]acrylamide derivative to produce a bio compatible
10 polymer. Preferred hydrophilic co monomers are hydrophilic [meth-]acryl- compounds such as carboxylic acids, [meth-] acrylamide derivatives, and the [meth-]acrylamide esters. The preferred aqueous solvent is deionized water, the solvent may also contain salts. Any biologically acceptable nonaqueous solvent that dissolves the polymer may also be used. In addition to the non-resorbable
15 gelling copolymer of N-isopropyl(meth-)acrylamide and (meth)acrylic acid, a biodegradable (resorbable) copolymer exhibiting similar gelation properties may also be used in polymer/ceramic composites that gel in response to physiological conditions. The biodegradable (resorbable) thermally gelling copolymer is obtained by grafting of the oligo(meth-)acrylamide derivative side chains on a
20 biodegradable polymer backbone. Examples of the suitable biodegradable polymers include, polysaccharides and poly(aminoacids). The preferred biodegradable polymers are degraded by enzymatic hydrolysis to non toxic, non irritating residues.

Other polymers include the polysaccharides such as chitosan. Chitosans
25 provide an additional new biodegradable component of polymer-ceramic composites suitable for injectable, resorbable templates for bone tissue regeneration. The rationale of using chitosans for this purpose is based on the fact that chitosan solutions gel in response to pH change from slightly acidic to physiological.

The unique aspect of this novel system is that at pH lower than 6.5 the chitosan-ceramic suspension is a paste-like flowable system, and at physiological pH the polymer undergoes a phase transition resulting in entrapment of ceramic component within the reversible gel matrix. Thus, application of pH-reversible gels enables the creation of an implant, which may be tailored to any shape of a bone defect needed to be filled. In contrast to the rapid setting gel/cement compositions, which harden without regard to whether they are placed into the physiological environment, the present invention hardens on exposure to the physiological conditions that occur only after they are placed into the body. As a consequence, the stimulus response compositions of the invention and practice of the method of the present invention provides a bone filling biomaterial which can be pre-mixed and placed in stages following a sterilization or other treatment without premature setting.

Other polysaccharides such as xanthan gum, (available from Kelco), locust bean gum (available from Aldrich), and carrageenan (available from Aldrich, mainly K-carrageenan) are also useful in the invention. Carrageenan is less preferred because it was found to cause irritation in an animal model.

Calcium phosphate ceramics are preferred for use as the ceramic component of implants in the repair of bone defects because these materials are non-toxic, non-immunogenic, and are composed of calcium and phosphate ions, the main constituents of bone. Both tricalcium phosphate (TCP) $[\text{Ca}_3(\text{PO}_4)_2]$ and hydroxyapatite (HA) $[\text{Ca}_{10}(\text{PO}_4)_6(\text{OH})_2]$ have been widely studied for this reason. Calcium phosphate implants may be osteoconductive, and have the apparent ability to become directly bonded to bone. As a result, a strong bone-implant interface can be created. However, the mechanical properties of calcium phosphate ceramics make them ill suited to serve as a structural element. Ceramics are brittle and have low resistance to tensile loading. For this reason, the ceramic component is combined with a polymeric component, which adds elastic strength to the composition, overcoming the shortcomings of the ceramic alone while retaining its positive features.

Other useful ceramics include other calcium or magnesium phosphates, aluminas, and the like. Any nontoxic, non-immunogenic ceramic may be substituted for calcium phosphate in special circumstances such as an application wherein resorption of the ceramic component is not desired. Calcium phosphate
5 ceramics have a degree of bioresorbability, which is governed by their chemistry and material structure. High density HA and TCP implants exhibit little resorption, while porous ones are more easily broken down by dissolution in body fluids and resorbed by phagocytosis. However, TCP degrades more quickly than HA structures of the same porosity in vitro. In fact, HA is relatively insoluble in
10 aqueous environments.

These solubility differences permit the use of mixed calcium phosphate ceramics to control the final structure of the implant by using for example TCP particles sized to be selectively dissolved by bodily fluids and provide voids in the final structure and HA particles sized to crystallize under physiological conditions
15 to provide a mineral matrix to foster bone ingrowth into the implant. Preferably, the voids will be in the range of 100 to 200 microns, the preferred size for supporting cell growth. Other non-toxic salts can be substituted for TCP for special purposes in forming voids in the implants. Implants having a macro porous structure which pores on the order of 100 to 200 microns are strongly
20 preferred, although pores may be smaller as in 50 to 150 microns, larger as in 100 to 300 microns, or cover a broader range as in 50 to 500 microns and still provide useful implants.

Bone repaired with the use of a conventional polymeric implant such as those described in U. S. Patent 5,626,861 will be required to be immobilized for
25 between six and eight weeks, the standard procedure for conventional fractures. Where the implants of the present invention permit less invasive surgery and in situ fixation, the healing time may be reduced.

All fractures are subject to static loading even while immobilized in a cast, i.e., there is a load resulting from the weight of the bone itself. In order for the
30 implant to unite bone segments in a fracture, it must have initial strength sufficient

to provide the stability necessary for healing to begin. Further, the implant must retain a degree of strength throughout the bone remodeling cycle. Strength retention in the implant is governed by the degradation rate of the polymer in the polymer-ceramic composite. Both high strength retention over time and rapid
5 weakening of the scaffold may be detrimental to the bone repair process. Slow implant resorption can shield immature skeletal tissue from the functional stresses necessary for complete remodeling. Conversely, rapid degradation may prematurely shift load bearing to the new bone and cause its collapse. Preparation of example implants is described below to illustrate the invention and not by way
10 of limitation. The examples are not intended to limit the invention, which is defined by the claims set out below.

Procedures and Sample Preparation

15 Xanthan gum solution was prepared by addition of the powder at room temperature with stirring into deionized water or sodium chloride solution with desired ionic strength. The resulting smooth solution was then allowed to stand overnight to release all air bubbles. Solutions of locust bean gum and carrageenan gum were prepared at 70-75°C and stirred until all powder is
20 dissolved.

Hydroxyapatite(HAP)-xanthan gum and HAP-locust bean gum pastes were prepared by mixing the desired amount of HAP powder (Aldrich) into the polysaccharide solution using either a magnetic stir plate (<30wt% HAP) or a mechanical stirrer at higher solids loading (>30wt% HAP). To prepare the HAP-
25 carrageenan paste, the carrageenan solution was maintained at 70-75°C in a water bath during mixing. Rheological measurements such as viscometry, strain sweep and oscillation were conducted using a Bohlin Rheometer.

HAP-polysaccharide paste samples prepared for mechanical testing and dissolution experiments were crosslinked in simulated blood plasma electrolyte
30 solution overnight at room temperature. The simulated blood plasma electrolyte

solution contains 3mM KCl, 1.5mM MgCl₂, 4.2mM NaHCO₃, 1.0mM KH₂PO₄, 138mM NaCl and 2.5mM CaCl₂. It was adjusted to pH 7.4 by the addition of NaOH solution before use.

HAP-polysaccharide paste samples for microstructure and porosity studies were prepared and crosslinked in simulated blood plasma electrolyte solution as described above. They were then cut into small rectangles and quickly frozen in liquid nitrogen, then dried in vacuum at -12°C for at least 24 hours.

HAP dissolution kinetics was measured using the constant composition method at 25°C. The in-vitro carrageenan leaching experiments were conducted in simulated blood plasma electrolyte solutions and concentration of leached carrageenan was determined by a colorimetric method using methylene blue.

Example 1

Rheological Studies of Calcium Phosphate-Binder Suspensions

The viscosity of HAP suspensions containing one of the three binders selected was measured as a function of binder properties, binder concentration, HAP solids loading and temperature.

Viscosity is a transport property. It must be sufficiently low to facilitate injectability. A shear-thinning behavior is desired. This means that at very low shear rates suspended HAP particles remain stationary because the high viscosity of the binder solution was below the yield point. Higher shear rates that are encountered during pouring or during vibration can effectively reduce the viscosity. As shown in Figure 1, all three slurries containing 30wt% HAP showed shear-thinning behavior. Among them, HAP suspension containing carrageenan had the lowest viscosity, even though the carrageenan concentration was higher (0.4wt%) than the other two binders (0.25wt%).

Solids loading had a great influence on viscosity as illustrated in Figure 2. The viscosity of these systems was almost constant with HAP solids loading equal

or below 30wt% as shown in Figure 3. Further increasing the solids loading to 40wt% dramatically increased the viscosity of the suspensions. As a matter of fact, the highest HAP loading achievable is about 43wt%. Above that, it became difficult to measure rheological properties.

5 Effect of temperature on gelation properties was also investigated. It is known that temperature up to 93°C has no effect on the viscosity of xanthan gum solutions. Locust bean gum solution, prepared at 70-80°C, also showed no significant changes in viscosity as the temperature was decreased. K-carrageenan solution, prepared at 70-75°C in a similar way to locust bean gum, formed a rigid
10 gel upon cooling. Its rheological behavior was investigated as a function of temperature. Temperature dependent viscosity measurements of carrageenan were started at 70°C and eventually cooled to 20-30°C in a water jacket of the rheometer.

As shown in Figure 4 at higher temperature (50-70°C), the suspension
15 containing 30wt% HAP and 2wt% carrageenan had low viscosity values. It formed a gel around 40°C, indicated by the sudden increase of viscosity. Below 40°C, the gel was fractured by applied shear force, resulting in the decrease of viscosity. A 2wt% carrageenan solution without HAP showed a similar temperature dependence (Figure 4). This thermal gelation property makes the
20 HAP-carrageenan suspension a good candidate as self-setting bone filling materials. It was fluid-like and injectable above 45°C, and formed a rigid gel at body temperature of 37°C.

Materials Characterization

25

The microstructure and porosity of HAP-carrageenan pastes were studied by scanning electron microscopy (SEM). These pastes were prepared at 70-75°C and cross-linked in simulated plasma electrolyte solution as described above. They were then cut into small rectangular pieces with rough dimension of 2.5cm x
30 0.5cm x 0.3cm. To preserve structures, they were quickly frozen in liquid

nitrogen, then dried in vacuum at -12°C for at least 24 hours. The dimension of each piece was measured using calipers before and after freeze drying to check on the shrinkage. While the samples containing 30wt% or 40wt% HAP and 2wt% carrageenan showed less than 5% shrinkage, a sample containing 10wt% HAP and 2wt% carrageenan shrank 10-20%, indicating a structure collapse during freeze drying. The SEM images of 30wt% and 40wt% HAP in 2wt% carrageenan are shown in Figure 5. The structure of the 30wt% HAP contained HAP agglomerates of 5-10 μm , and pores ranging from 5-15 μm throughout the monolith. An increase of HAP loading to 40wt% produced denser material and reduced pore size to less than 5 μm .

HAP dissolution by constant composition method

The kinetics of HAP dissolution of HAP-carrageenan pastes was studied by constant composition (CC) techniques. An undersaturated solution containing 0.125mM CaCl_2 and 0.075mM KH_2PO_4 and 0.15M NaCl was prepared by mixing stock solutions of 0.1M CaCl_2 and 0.1M KH_2PO_4 in 0.15M NaCl. The solution pH was adjusted to 6.5 using 0.1M KOH solution. Nitrogen, saturated with water vapor, was purged through the prepared solution to exclude carbon dioxide. A combination pH electrode (Corning) was used as a probe to monitor solution pH. An amount of 0.083g of 30wt% HAP-2wt% carrageenan paste was weighed and added to the under saturated solution to initiate the dissolution experiment. The solution pH was kept constant by the potentiostatic-controlled addition of 0.30M NaCl and 0.007M HCl. The rate of dissolution was calculated from the rate of addition of the acid after correcting for the volumes required to maintain constant pH. For comparison, the dissolution rate of 0.025g HAP powder, same amount of HAP as in HAP-carrageenan paste, was measured using the same technique [Figure 6]. The CC results indicated both samples have high initial rates, and dissolution slowed down as more and more calcium and phosphate ions accumulated in the solutions. HAP-carrageenan paste had a lower initial

dissolution rate than the free HAP powders. As the carrageenan gradually leached out, the HAP-carrageenan paste became loosely attached and acted more like free particles.

5 Carrageenan leaching studies in simulated blood plasma electrolyte solutions

Suspensions containing 2wt% carrageenan and 0 to 40wt% HAP were prepared at 75°C. They were poured into small weighing dishes and formed blocks upon cooling to 37°C. After weighing each block (about 8 gram), each
10 block was placed in 20 ml of simulated blood plasma solution at 37°C. Periodically, the solution was collected and replaced with new solution. The HAP powder that was remaining in the solution was separated by centrifugation. The clear solution samples were diluted and mixed with methylene blue. The concentrations of carrageenan were determined by measuring adsorption at 559nm.
15 against a standard calibration curve. The result is shown in Figure 7.

Among the paste samples tested, those containing less than 20wt% HAP were softened and broken down after 24 hours. Therefore, no data was available after this period. At higher HAP loading, the blocks maintained shape. The results indicated that as the HAP solid loading increased, the rate of carrageenan
20 leaching decreased.

In vivo Results

Implants prepared according to the above procedure with carrageenan were
25 placed in an induced bone defect in mice and produced an acute adverse response. Thus, while carrageenan is an attractive candidate material based on physical properties, it was found to lack biological compatibility when formulated as a polymer/ceramic composite. The high dissolution rate of carrageenan may contribute to the adverse response. Although the carrageenan illustrates the

desirable physical properties of the invention, it may not be useful in the method of the invention if it is unsuited to implantation in a mammalian body.

Example 2

5

Chitosan study

Methods

High molecular weight (HMW) chitosan, $1.1-1.6 \times 10^6$ D, was purchased from Aldrich Chemical Company, Inc., low molecular weight (LMW) chitosan, 70 KD, was purchased from Fluka Chemie. Chitosans were dissolved in 0.1N HCl and purified before use by precipitation into acetone/water mixture. Hydroxyapatite (HAP), tricalcium phosphate (TCP), Bovine serum albumin (BSA), 5-fluorouracil (5-FU), were purchased from Sigma Chemical Company, and used as received. Phosphate buffered saline (PBS), pH 7.4 was used as a release medium in BSA and 5-FU release experiments.

15

Preparation of chitosan-HAP and chitosan-TCP suspensions

Solutions containing 0.5-2 wt% of purified chitosan were prepared in 0.1N HCl. Chitosan-HAP or -TCP suspensions were prepared by simple mixing of the ceramic component with chitosan solution. Suspensions containing 20-45 wt% of HAP and 30-50 wt% of TCP were prepared.

20

Compressive modulus measurements

25

Experiments were performed using Dynamic Mechanical Analyzer equipped with the stainless-steel parallel plate measuring system. Compressive modulus was determined by using a uniaxial, unidirectional compressive deformation. The samples, in the form of cylindrical disks, were held in place

30

initially with a minimal static stress, then the static stress was increased. The response of the sample (static strain) was used to calculate the static compressive modulus.

5 Release of model compounds

The release of 5-FU and BSA from chitosan-HAP or -TCP composites was conducted in PBS, pH 7.4 at 37°C. A cylindrically shaped samples of the composites were cured in a small diameter dialysis tubing. The amount of released compounds was determined by monitoring UV absorption of the release medium at 266 and 280 nm for the 5-FU and BSA, respectively. To maintain sink conditions, samples were transferred into fresh release medium at predetermined time intervals. The release kinetics data were reported as fraction of the total amount released versus time.

15

Results

In order to obtain chitosan-calcium phosphate composites suitable for the injectable, resorbable scaffolds for bone tissue regeneration, several properties of the composites need to be investigated and optimized. The most important requirements are the following: bio compatibility of the materials and their degradation products, injectability of the polymer-ceramic suspensions, suitable gelation kinetics of the composites, controlled degradation rates, ability to release small and large therapeutic agents and finally osteoconductivity. As a consequence of the above requirements, experiments have focused on the investigation and optimization of the following properties: rheological properties of the suspensions, and water content, porosity, compressive strength, and degradation rate of the cured composites. The ability of the composites to release therapeutic agents was also evaluated.

30

Chitosan-calcium phosphate suspensions: preparation and rheological properties

Chitosan dissolves in diluted acids at pH 2-3, but the pH of the obtained
5 solution may be titrated up to a pH of 6 with no change in polymer solubility.
Therefore, chitosan-ceramic suspensions may be prepared at a wider pH range, i.e.
2-6. The pH of chitosan solution is important, since it affects the solubility of the
calcium phosphate phase of the composite.

Rheological properties of chitosan solutions and chitosan-calcium
10 phosphate suspensions were investigated as a function of chitosan concentration,
molecular weight, content and type of a calcium phosphate phase (HAP or TCP).

As illustrated in Figure 8, chitosan-HAP suspensions containing up to 40
wt% of HAP phase exhibited viscosities and flow suitable for injectable bone
paste applications.

15

Compressive modulus

Compressive modulus is a measure of the resistance of the sample to
compression and is an indicator of stiffness or rigidity. Relative compression
20 moduli were determined to assess the changes in mechanical properties of the
polymer-ceramic composites resulting from the gelation of the polymeric
component. The compressive moduli were determined for a series of polymer-
ceramic composites differing in composition in terms of ceramic (HAP or TCP),
as well as polymeric components (LMW or HMW chitosan). Results are
25 presented in Figures 9 and 10. The effect of solids loading, i.e., the amount of
ceramic phase in the composite, on the compressive modulus of HMW chitosan-
HAP composite is illustrated in Figure 9. Composites with higher solids loading,
40 wt% , demonstrated higher relative compressive modulus as demonstrated by
a steeper slope of the stress strain curve. A similar trend was observed for the
30 chitosan TCP composites. The effect of the ceramic phase type is illustrated in

Figure 10. Composites containing HAP demonstrated higher relative compressive moduli than composites containing TCP. The trend was similar for both chitosans HMW and LMW (results not shown). The results of compressive modulus studies clearly demonstrated that the chitosan-calcium phosphate composites in a gelled state maintain mechanical integrity in contrast to the flowable, injectable properties of the corresponding suspensions.

Release of model compounds

Different therapeutic and osteoconductive agents may be incorporated into the thermally reversible polymer-ceramic composites as needed. Examples of therapeutic agents include antibiotics for the local treatment of possible infections, anticancer agents for the site-specific treatment of bone tumors. Examples of osteoconductive agents include growth factors and bone morphogenic proteins. In order to assess the possibility of using our novel polymer-ceramic composites as delivery vehicles for therapeutic and/or osteoconductive agents, we have investigated the release of model low and high molecular weight compounds.

An anticancer agent, 5-fluorouracil (5-FU) was used as a model low molecular weight compound, and bovine serum albumin (BSA) was used as a model macromolecule. The results of the release experiments are presented in Figures 11 and 12. In Figure 11, the effect of two calcium phosphate ceramic phases are compared, showing a small rate advantage to HAP over TCP. As illustrated in Figure 12, the release of 5-FU and BSA demonstrated different kinetics. While 5-FU released from the chitosan-TCP composite within 10 hours, BSA release was much less rapid and lasted for 40 hours. These results may be explained by the differences in the effective size of the releasing molecules. BSA, being a macromolecule, demonstrated slower release kinetics due to the lower effective diffusion coefficient within the polymer-ceramic matrix. The release results demonstrated that chitosan-calcium phosphate composites may be used as

a matrix for the release of therapeutic agents and proteins such as growth factors and bone morphogenic proteins.

CLAIMS:

We claim:

1. A composition, comprising at least two phases: a biologically compatible polymer or polymer solution that forms a gel under physiologically controlled parameters and a biologically compatible ceramic component; the composition being fluid under non-physiological conditions and non fluid under physiological conditions.
2. A composition according to claim 1, wherein the polymer or polymer solution is selected from the group consisting of resorbable polymers, non resorbable polymers, natural polymers, synthetic polymers and the aqueous or non aqueous solutions thereof and combinations thereof.
3. A composition according to claim 1, wherein the polymer is selected from the group consisting of polysaccharides, polyamides, polyamino acids and combinations thereof.
4. A composition according to claim 1 wherein the polymer forms a gel on exposure to a pH in the range of 4 to 9.
5. A composition according to claim 1 wherein the polymer forms a gel on exposure to a temperature in the range of 35 to 40°C.
6. A composition according to claim 1 wherein the polymer forms a gel on exposure to an ionic strength of about 0.15.
7. A composition according to claim 1 which comprises a therapeutic agent.

8. A composition according to claim 7 wherein the therapeutic agent is selected from the group consisting of bone growth factors, antibiotics, chemotherapy drugs, radioisotopes, osteoconductive factors, bone morphogenic proteins and cytokines.

5 9. A composition according to claim 1 which comprises a hydroxyapatite ceramic, or a tricalcium phosphate ceramic or mixtures thereof.

10 10. A composition according to claim 9 which comprises chitosan, xanthan gum, locust bean gum.

11. A composition according to claim 1 which comprises voids.

12. A composition according to claim 11 wherein the voids have a cross
15 section in the range of 100 to 200 microns.

13. A method of forming a solid implant in a mammalian body which comprises the steps of mixing a biologically compatible gel forming component with a ceramic or a ceramic forming component providing a fluid mixture, and
20 placing the fluid mixture into a mammalian body wherein the fluid mixture gels after placement in the mammalian body in response to a stimulus provided by conditions present or induced in the mammalian body.

14. A method according to claim 13 wherein the polymer is selected
25 from the group consisting of resorbable polymers, non resorbable polymers, natural polymers and synthetic polymers and the aqueous or non aqueous solutions thereof.

15. A method according to claim 14 wherein the polymer is selected
30 from the group consisting of polysaccharides, polyamides or polyamino acids.

16. A method according to claim 13 wherein the polymer forms a gel on exposure to a pH in the range of 4 to 9.

5 17. A method according to claim 13 wherein the polymer forms a gel on exposure to a temperature in the range of 35 to 40°C.

18. A method according to claim 13 wherein the polymer forms a gel on exposure to an ionic strength of about 0.15

10 19. A method according to claim 13 which comprises the step of mixing a therapeutic agent with the fluid mixture.

20. A method according to claim 19 wherein the therapeutic agent is
15 selected from the group consisting of bone growth factors, antibiotics, chemotherapy drugs, radioisotopes, osteoconductive factors, bone morphogenic proteins and cytokines.

21. A method according to claim 13 which comprises the further step of
20 mixing a material into the fluid mixture which produces voids in the gelled fluid mixture.

22. A method according to claim 13 wherein the material produces voids having a cross section on the order of 50 to 500 microns.

25

1/12






Fig. 1


2/12

*Fig. 2*

3/12

*Fig. 3*

4/12

*Fig. 4*

5/12




Fig. 5a






Fig. 5b


6/12

*Fig. 6*


7/12

*Fig. 7*


8/12

*Fig. 8*


9/12

*Fig. 9*


10/12

*Fig. 10*

11/12

*Fig. 11*

12/12

*Fig. 12*

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/20803

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 A61L25/00 A61L27/00.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 4 478 822 A (HASLAM JOHN L ET AL) 23 October 1984 cited in the application see column 2, line 41 - column 5, line 30 -----	1-10, 13-20
Y	EP 0 298 501 A (ASAHI OPTICAL CO LTD) 11 January 1989 see page 3, line 28 - page 5, line 7 see example 1 -----	1-10, 13-20

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

12 February 1999

Date of mailing of the international search report

09/03/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Heck, G

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/20803

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.: CLAIMS 13-22
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Although claims 13-22 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by surgery

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/US 98/20803

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4478822 A	23-10-1984	CA 1224148 A	14-07-1987
		DE 3484969 A	02-10-1991
		DK 233884 A, B,	17-11-1984
		EP 0126684 A	28-11-1984
EP 0298501 A	11-01-1989	JP 1018949 A	23-01-1989
		JP 1842719 C	12-05-1994
		JP 1100048 A	18-04-1989
		JP 2563186 B	11-12-1996
		JP 1100049 A	18-04-1989
		JP 2563187 B	11-12-1996
		DE 3855611 D	14-11-1996
		DE 3855611 T	06-03-1997
		DE 3869850 A	14-05-1992
		DE 3872862 A	20-08-1992
		EP 0323632 A	12-07-1989
		EP 0436499 A	10-07-1991
		JP 1948678 C	10-07-1995
		JP 2077261 A	16-03-1990
		JP 6077598 B	05-10-1994
		JP 1100039 A	18-04-1989
		JP 2662984 B	15-10-1997